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Abstract
Background: Phase III randomised controlled trials aim not just to increase the sum of human knowledge, but also
to improve treatment, care or prevention for future patients through changing policy and practice. To achieve this,
the results need to be communicated effectively to several audiences. It is unclear how best to do this while not
wasting scarce resources or causing avoidable distress or confusion. The aim of this systematic review is to examine
the effectiveness, acceptability and resource implications of different methods of communication of clinical research
results to lay or professional audiences, to inform practice.
Methods: We will systematically review the published literature from 2000 to 2018 for reports of approaches for
communicating clinical study results to lay audiences (patients, participants, carers and the wider public) or professional
audiences (clinicians, policymakers, guideline developers, other medical professionals). We will search Embase, MEDLINE,
PsycINFO, ASSIA, the Cochrane Database of Systematic Reviews and grey literature sources. One reviewer will screen titles
and abstracts for potential eligibility, discarding only those that are clearly irrelevant. Potentially relevant full texts will then
be assessed for inclusion by two reviewers. Data extraction will be carried out by one reviewer using EPPI-Reviewer. Risk
of bias will be assessed using the relevant Cochrane Risk of Bias 2.0 tool, ROBINS-1, AXIS Appraisal Tool or Critical
Appraisals Skills Programme Qualitative Checklist, depending on study design. We will decide whether to meta-analyse
data based on whether the included trials are similar enough in terms of participants, settings, intervention, comparison
and outcome measures to allow meaningful conclusions from a statistically pooled result. We will present the data in
tables and narratively summarise the results. We will use thematic synthesis for qualitative studies.
Discussion: Developing the search strategy for this review has been challenging as many of the concepts (patients,
clinicians, clinical studies, and communication) are widely used in literature that is not relevant for inclusion in our review.
We expect there will be limited comparative evidence, spread over a wide range of approaches, comparators and
populations and, therefore, do not anticipate being able to carry out meta-analysis.
Systematic review registration: International Prospective Register of Systematic Reviews PROSPERO (CRD42019137364).
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Background
Phase III randomised controlled trials are often costly and
can take years to carry out [1]. They may involve hundreds
or thousands of participants, cared for by clinicians,
nurses and other medical professionals at many sites. They
aim not just to increase the sum of human knowledge, but
also to improve treatment, care or prevention for future
patients. To achieve this, the results need to be communi-
cated effectively to a variety of audiences [2].
The evidence base on how best to communicate trial re-
sults to different audiences is sparse [2]. These gaps in evi-
dence mean that scarce time and resources may be wasted
in carrying out ineffective communications activities,
while approaches that do work may not be widely used.
There is also a risk that some communication approaches
may be harmful, for example causing avoidable distress or
confusion [3, 4]. This systematic review will draw together
what evidence there is, in order to inform the practice of
clinical trials units and others who are interested in effect-
ively communicating trial results.
The aim of this study is to examine the effectiveness, ac-
ceptability and resource implications of different methods
of communication of clinical research results to lay (study
participants, patients, carers, communities, populations at
risk of the condition, and the wider public) and profes-
sional audiences (medical professionals, policymakers, clin-
ical guideline developers and healthcare commissioners).
We are primarily interested in evidence on communicating
the overall results of phase III academic clinical trials but
will also look at the literature on communicating the re-
sults of other clinical research study designs that are likely
to generate evidence with direct implications for policy and
practice (for example, systematic reviews and cohort stud-
ies) in order to learn lessons that may also be applicable to
phase III academic clinical trials. We will try to encompass
all approaches to communication that have been evaluated
in the literature.
This systematic review will build on two prior reviews of
communicating the results of clinical research, identified
through scoping searches of the PubMed database during
the initial planning phase of this review. The first of these
was a systematic review by the Agency for Healthcare Re-
search and Quality (AHRQ) [2], which looked at several
questions around the communication and dissemination
strategies to facilitate the use of health-related evidence.
Of most relevance to this review is the comparative effect-
iveness of the dissemination strategies to promote the use
of health care evidence and how this varies by patients and
clinicians. They focused on strategies to increase reach of
information, motivation to use and apply evidence, ability
to use and apply evidence, or used a multicomponent ap-
proach (combining two or more approaches to increase
the reach of the evidence, the motivation of the audience
to apply the information, and/or the ability to use the
evidence). They found that evidence was poor, inconsistent
or not statistically significant for most of the comparisons
they looked at. The most successful strategy identified in
the review was the use of a multicomponent dissemination
approach for clinicians when trying to change their behav-
iours. This review will complement the AHRQ review by
including qualitative and nonexperimental studies along-
side trials of communication approaches, to provide a
broader understanding of approaches that are being used
to communicate health research, as well as look at com-
parative evidence that has been generated since the AHRQ
review. The second literature review looked at commu-
nicating the results of clinical research to participants
[5] and found that research participants wanted to be
informed of the results of the studies they had taken
part in and that investigators seemed to support the
communication of aggregate results to participants.
Our scoping search of the PROSPERO database did not
reveal any other relevant systematic reviews to
consider.
Our review will also complement a study currently be-
ing carried out to look at communicating results to trial
participants (the REporting Clinical trial results Appropri-
ately to Participants (RECAP) study) [6]. In addition to
study participants, we will also look at communicating re-
sults to wider lay audiences (including patients who are
not participating in the trial, and the wider public) and
professional audiences including policymakers, guideline
developers and clinicians.
This review will cover a broad range of approaches of
communicating study results to lay and professional audi-
ences. As there are very different resource implications for
the different methods of communicating results, this
review will compare the effectiveness and acceptability of
different methods and will also comment on resource im-
plications. It will look at a variety of outcomes, covering all
dimensions of the International Association for the Meas-
urement and Evaluation of Communication Framework
(outputs, outtakes (what the audience take from the com-
munication, e.g. awareness or understanding), outcomes
and impact) [7]. Where there is sufficient evidence, we will
seek to make recommendations on which approaches are
likely to be the most effective, cost-effective and/or accept-
able for communicating with different audiences, in order
to guide future practice and avoid effort and resources
being wasted on ineffective approaches.
Objectives
Our overarching research question is what are the best
ways or combinations of ways of communicating the re-
sults of clinical research that has implications for health
policy or practice to lay and professional audiences?
Within this, we will look at three key questions:
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1. How effective are different approaches to
communicating the results of clinical research to:
a. Clinicians (beyond those that were involved in
the study)
b. Policymakers, guideline developers and
healthcare commissioners
c. Study participants and their carers
d. Other lay audiences, including patients and the
public?
2. What factors influence the effectiveness of different
approaches to communicating the results of clinical
research?
3. What are the views and experiences of different
audiences about how the results of clinical studies
are communicated to them, and what are the views
and experiences of those involved in
communicating the results of clinical studies to
these audiences around how this is done?
Methods
This protocol will be reported according to the
PRISMA-P statement. Our PRISMA-P checklist is in-
cluded as Additional file 1.
Eligibility criteria
Studies will be selected according to the criteria outlined
below.
Study designs
We will include any reports of studies with any qualitative
or quantitative study design, as well as theoretical papers,
health economic papers, reviews, reports and guidelines.
Population
Eligible participants will include lay audiences and pro-
fessional audiences, as defined below.
Lay audiences
 Clinical study participants and their carers, the
wider patient community, including individual
patients, carers, and patient groups
 Communities in which the studies have taken place
(geographic or other demographic communities)
 Populations at risk of the condition
 The wider public
Professional audiences
 Medical professionals (beyond those involved in
conducting the trial), including individual
practitioners, organisations (e.g. hospitals or medical
schools) and professional associations/societies
 Policymakers
 Clinical guideline developers
 Healthcare commissioners
We will not restrict the population by age, sex, location
or other demographic factors.
Approaches
For the purposes of this review, we are interested in any
approaches for communicating study results to any of the
populations specified above. We are interested in commu-
nicating the results of clinical studies carried out on
humans that have implications for health policy or practice.
By clinical studies, we mean observational or interventional
medical research relating to treatment, diagnosis or disease
prevention among actual patients/people, rather than
laboratory or modelling studies. We anticipate that this will
include approaches to communicating the results of phase
III academic randomised controlled trials, including cluster
randomised trials; meta-analyses; epidemiological studies
that look at treatment, prevention or diagnosis approaches;
industry-sponsored phase III randomised controlled trials;
and possibly phase II randomised controlled trials if their
results have implications for practice and/or policy. As we
will include studies without a comparator group in this sys-
tematic review, we are not restricting the search to studies
with a particular comparator.
Outcomes
For question 1 (effectiveness), we are interested in a broad
range of outcomes (Table 1), so the types of outcomes
reported will not be an inclusion or exclusion criterion.
Timing
The time point of enrolment and the duration of interven-
tions will not be considered as eligibility criteria. There
will be no restrictions by length of follow-up of outcomes.
Setting
We will not restrict the search to specific settings but
will collect data on the settings in which studies have
been carried out and seek to assess whether there is het-
erogeneity of effect based on setting.
Minimum sample size
We will not restrict studies by sample size, as this
would be inappropriate when including qualitative
research, or studies where the intended audience may
be small (e.g. policymakers).
Language
We will include articles reported in English. We will ex-
clude articles written in other languages, due to resource
constraints.
Types of publication
The types of publications we will include are:
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 Complete articles
 Conference abstracts
 Reports (grey literature)
 Theses
We will exclude commentaries, editorials, guidelines,
letters and protocols.
Information sources
Literature search strategies will be developed using med-
ical subject headings (MeSH) and text words. We will
search the following databases:
 Embase (Ovid interface)
 MEDLINE (Ovid interface)
 PsycINFO (Ovid interface)
 ASSIA
 Cochrane Database of Systematic Reviews
We will also search the following grey literature
sources for items:
 ProQuest Dissertations and Theses Global
 The INVOLVE evidence library
 The National Coordinating Centre for Public
Engagement’s resources
 Conference proceedings from the Society of Clinical
Trials’ annual meetings
 Conference proceedings from the International
Clinical Trials Methodology Conference
 Conference proceedings from the Engage conference
 Cochrane Colloquium abstracts
We will search these databases and information sources
for records from January 1, 2000, onwards. We have
chosen this time period as there have been considerable
developments in the use of communication technologies
since 2000 (e.g. email, internet and mobile phones), which
may have implications for the communication of study
results. In addition, a scoping search revealed that very
little had been published on this topic prior to 2000, which
supports this decision.
We will scan the reference lists of key included studies
and relevant reviews and guidelines identified through
the search, to identify papers that our search has missed.
We will contact experts in the field, to ask what studies
they are aware of that we should make sure we include.
Search strategy
No study design limits will be imposed on the search. The
search strategy was developed by AS, who is a PhD
student, under the guidance of CV, who is a specialist in
systematic reviews, with advice from an information spe-
cialist. AS, CV and JB contributed to the development of
search terms and reviewed the final strategy. The strategy
was developed and pilot tested in the EMBASE database,
using the Ovid interface, using an iterative approach until
a strategy that was sufficiently sensitive but did not result
in an unmanageable number of records was achieved. The
strategy will be adapted to the syntax and subject headings
of other databases, including MEDLINE, PsycINFO and
ASSIA as necessary.
Some of the grey literature sources have less sophisti-
cated search functions. For these, we will use broad
search terms, and hand search the results to identify
those that are potentially relevant for this review. The
searches will be updated until the study completion date,
which is anticipated to be around early 2022.
Two searches will be run: one to identify articles rele-
vant to communicating results to lay audiences and the
other to identify articles relevant to communicating re-
sults to professional audiences. This is because a differ-
ent terminology is needed to identify communication
approaches for professional audiences compared to lay au-
diences. Figure 1 illustrates the concepts of our search.
Each search will combine results from searches focusing
on terms for the audience, with results from searches with
terms for communication and clinical research. Add-
itional file 2 shows the list of search terms used. These will
be combined with adjacency rules applied to limit results
Table 1 Outcomes we expect to find information on, by audience
Outputs Outtakes Outcomes Impact
Lay audiences Demand
uptake/reach
Awareness
Knowledge
Understanding/
comprehension/clarity
Reaction to the results
Attitude to the results (interest, consideration)
Satisfaction with how the results have been
communicated/the information provided
Satisfaction with taking part in the study
Willingness to take part in future research
Reported likelihood of recommending
that others take part in research
Changes in behaviour based on results
Professional
audiences
Demand
uptake/reach
Awareness
Knowledge
Understanding/
comprehension/clarity
Attitude to the results (e.g. interest,
consideration, support)
Changes in practice
Changes in policy
Changes in guidelines
Research
communicators
Practice costs Barriers to
communicating results
Facilitators to
communicating results
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to articles where the audience terms, communication
terms and clinical research terms are within a certain
number of words from each other. Where databases allow
us to use this adjacency approach, we will not use MeSH
terms in our searches, as we are confident that articles
that are relevant to our review will be identified through
use of terms relating to audience, communications and
clinical research in their titles, abstracts and keywords,
and it is unclear how keywords about patients or clinical
research are applied, given how common these are in the
medical literature. Where the adjacency approach cannot
be used, we will use MeSH terms for communication to
narrow down results.
Study records
Data management
Search results will be downloaded into Endnote. The cita-
tions will then be imported into Covidence (www.covi-
dence.org) for abstract and title screening. Covidence will
be used to record eligibility decisions. Selected records will
then be imported into EPPI-Reviewer Version 4.7.0.0 [8]
for data extraction.
Selection process
AS will assess the eligibility of titles and abstracts identi-
fied from electronic searches against the eligibility criteria
of the review, discarding only those that are duplicates or
clearly irrelevant. She will retrieve full-text copies of all
articles judged to be potentially eligible. AS and CV will
then independently assess all retrieved articles for inclu-
sion. AS and CV will meet regularly during the screening
process to discuss any issues arising and to ensure the
eligibility criteria are being applied consistently. In cases
where the two reviewers disagree on whether an item is
eligible, this will be resolved by discussion between AS,
CV and a third author where necessary. Where there is in-
sufficient information in the publication to assess its eligi-
bility, we will seek additional information from the study
authors. All potentially relevant papers excluded from the
review at this stage will be listed as excluded studies, with
reasons provided in the characteristics of excluded studies
table. The reviewers will not be blind to the journal titles
or to the study authors or institutions.
We will not use quality criteria as an inclusion criterion,
but will assess the quality of included studies and report
on that in our synthesis. If we find many records, we may
restrict the synthesis to those judged to be at low risk of
bias. See the “Assessment of risk of bias in included stud-
ies” section for how we will assess the quality of studies.
Data collection process
AS will carry out data extraction using standard electronic
forms to tabulate the required information in EPPI-
Reviewer. This will include information about the study
design, setting, results to be communicated, communica-
tion approach(es) used, target audience and outcomes.
The form will be based on the Cochrane Consumers and
Communication Group’s data extraction template,
adapted to fit the needs of this review. There will be differ-
ent versions of the form for quantitative and qualitative
studies, to allow different risk of bias assessment tools to
be applied and different types of data to be recorded. Draft
data collection forms are included as Additional file 3.
The forms will be piloted on the first 5 studies of each
type and adapted as needed. If the piloting leads to
changes to our plans, we will be transparent about this
when we report the review. Where there are multiple re-
ports from a single study, the most recently published data
on each available outcome will be recorded. If important
data about outcomes or approaches are missing, we will
contact authors to request this information.
Data items
We will collect information about:
 The article type, publication year, citation and
contact details for authors
 The study it refers to communicating the results of
(design, population, setting, disease, time period and
funding)
 The study methods for this report
 The participants included
 The approaches to communications studied
 The outcome measures
 The results/findings and interpretation
 Risk of biasFig. 1 Concepts of the search strategy
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Outcomes and prioritisation
We will classify outcomes in line with the International
Association for Measurement and Evaluation of Commu-
nication (AMEC) framework [7], which splits measure-
ments and insights into outputs, outtakes (the response
and reactions of the audience to the activity), outcomes
(the effect of the communication on the target audience)
and impact (changes the audience make as a result of the
communication). Table 1 outlines the outcomes that we
expect to find information on (although they will not all
be relevant for every study). We may find additional out-
comes that fit within this framework. Our primary out-
comes are shown in italics. For participants, the co-
primary outcomes are understanding and satisfaction with
how the results are communicated. For other patients,
communities and the public, we have chosen understand-
ing as our primary outcome. For clinicians and policy-
makers, our co-primary outcomes are changes in the
recommendations made in clinical policy documents, and
clinical guidelines published by professional bodies or gov-
ernment agencies, and changes in clinical practice. We are
also interested in the costs of the approaches tested. We
will not set time points for measuring primary or second-
ary outcomes but use those reported in eligible studies.
The qualitative synthesis will focus on research ques-
tion 2 (factors that influence the effectiveness of differ-
ent communication approaches) and 3 (the views and
experiences of audiences and communicators with re-
gard to the communication of research results).
The AHRQ review reported a lack of consensus regard-
ing definitions of key terms, particularly those describing
different dissemination strategies. As there are no widely
agreed standardised approaches to measuring the outcomes
listed in Table 1, we will accept different definitions and
approaches to the measurement of outcomes, as reported
in retrieved studies, but will note how they have been
defined by the authors.
Assessment of risk of bias in included studies
We will apply the risk of bias tool according to the pertin-
ent study design. If any RCTs of communication ap-
proaches are found, we will use the Cochrane ‘RoB 2.0’ tool
[9]. Any cluster randomised trials will be assessed by the
Cochrane ‘R0B 2.0 for cluster randomised trial when inter-
est is in the effect of assignment to intervention’ template
[9]. Cohort studies and case-control studies will be assessed
using the ROBINS-I tool [10]. Cross-sectional studies will
be assessed using the AXIS tool [11]. Qualitative papers se-
lected for inclusion will be assessed for methodological
quality using the CASP Qualitative Checklist [12], which is
one of the tools recommended by the Cochrane Qualitative
and Implementation Methods Group for assessing the
quality of qualitative studies with a range of methods [13].
For other types of studies, the most appropriate tool for
assessing risk of bias will be applied.
Data synthesis
Narrative synthesis
We will group the data based on the category that best
explores the heterogeneity of studies and makes the most
sense to the reader (i.e. by interventions, populations or
outcomes). Within each category, we will present the data
in tables and narratively summarise the results. Informa-
tion will be presented in the text and tables to summarise
the characteristics and findings of the included studies.
The narrative synthesis will explore the relationship and
findings both within and between the included studies.
We will use thematic synthesis for qualitative studies.
Results will be presented in order of key question, and,
within the section on key question 1, we will present the
primary outcomes first, followed by the other outcomes
in the order of outputs, outtakes, outcomes and impact.
If we find many studies relating to a communication
approach to similar audiences, we may exclude from the
synthesis those at high risk of bias. If we do not find
large numbers of comparable studies, we will retain
studies of any level of risk of bias in our analyses, but
ensure that the narrative considers the impact that the
level of risk of bias has on the certainty of any conclu-
sions drawn. If there is sufficient information available,
we will seek to explore whether the effectiveness of com-
munication approaches varies by the target audience
(e.g. lay vs professional audiences, participants vs other
patients, patients vs general population), disease or geo-
graphical location, or other factors identified from the
qualitative synthesis.
For qualitative studies, we will accompany the narra-
tive synthesis with a summary of the assessment of qual-
ity for the included studies and how methodological
limitations may affect our confidence in the synthesised
findings, as recommended by the Cochrane Qualitative
and Implementation Methods Group [13].
Following the GRADE guidelines, we will grade the over-
all quality of the synthesised quantitative evidence for each
outcome separately as high, moderate, low or very low,
taking into account the risk of bias, effect size, consistency
of results, directness of evidence, precision and risk of pub-
lication bias [14].
Meta-analysis
We do not think that formal meta-analyses will be possible
because of the anticipated variability in the populations, in-
terventions and outcomes of the included studies. However,
we will conduct such quantitative syntheses in the case of
(1) low risk of bias in the included studies, (2) consistent
outcomes between studies, (3) low publication bias, (4) a
high number of included studies and (5) low heterogeneity
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[15, 16]. We will apply the random effects model when
undertaking a meta-analysis. If we are unable to pool the
data statistically using meta-analysis, we will provide clear
reasons for this decision.
Meta-biases
We will carry out extensive literature searches that in-
clude the grey literature as well as published studies in
order to limit the impact of publication bias on our re-
view. We will also make careful assessments of potential
multiple publications from a single study, to ensure we
are not double counting results. We will also ask key
stakeholders what they think are the key studies in this
area, to ensure our search has identified them.
Where protocols for studies have been published, we
will check for differences between the protocol and the
final study, to assess whether there has been selective
outcome reporting. Where insufficient information is
available from the published report, we will contact the
authors for further information.
Discussion
Through conducting this review, we hope to bring to-
gether the existing evidence on how best to communicate
the results of clinical research to lay and professional audi-
ences, in terms of effectiveness, acceptability and resource
requirements, in order to inform practice.
Developing the search strategy for this study has been
challenging as many publications that are unrelated to our
topic use combinations of the search terms and concepts
used (e.g. participants, clinicians, clinical studies, report,
disseminate), resulting in very large numbers of records if
our three concepts (lay or professional, communication
and clinical research) are combined with AND. The adja-
cency approach has been developed to improve the specifi-
city of results from the searches, with the number of
words within which the three concepts have to appear be-
ing determined based on comparing results from different
limits (e.g. adjacent within 5 words compared to adjacent
within 6 words), to see at what point adding extra words
identifies very few extra relevant records.
Previous reviews, looking at subsets of the audiences
we are interested in, have found very heterogeneous
studies in terms of interventions and outcome measures,
making meta-analysis challenging. As our review is look-
ing at a wide range of audiences, interventions and out-
comes, we expect that we may not be able to carry out
meta-analyses. Once we have carried out the screening
and data extraction, we will make a decision on whether
meta-analysis is appropriate.
A limitation of this review is that title and abstract
screening will be carried out by only one reviewer, which
could result in potentially relevant records being ex-
cluded. In order to reduce this risk, the single reviewer
will include any records where there is doubt about their
eligibility at this stage of the review.
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